Caption Management’s Xenon Pharmaceuticals XENE Stock Holding History

Caption Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57.1M	Buy	982,200 +692,200	+239%	+$31.9M	0.33%	59
2025 Q4	$13M	Buy	290,000 +190,000	+190%	+$7.98M	0.09%	264
2025 Q3	$4.01M	Sell	100,000 -131,700	-57%	-$4.64M	0.03%	580
2025 Q2	$7.25M	Sell	231,700 -25,000	-10%	-$815K	0.08%	296
2025 Q1	$8.61M	Buy	+256,700	New	+$9.75M	0.08%	237
2024 Q2	–	Sell	-248,300	Closed	-$10.7M	–	1557
2024 Q1	$10.7M	Sell	248,300 -52,900	-18%	-$2.43M	0.16%	146
2023 Q4	$13.9M	Buy	301,200 +223,700	+289%	+$7.9M	0.19%	134
2023 Q3	$2.65M	Buy	+77,500	New	+$2.9M	0.04%	508
2023 Q2	–	Sell	-50,000	Closed	-$1.79M	–	1443
2023 Q1	$1.79M	Sell	50,000 -153,100	-75%	-$5.66M	0.03%	471
2022 Q4	$8.01M	Buy	+203,100	New	+$7.4M	0.12%	202
2021 Q4	–	Sell	-704,200	Closed	-$10.8M	–	1986
2021 Q3	$10.8M	Buy	+704,200	New	+$12.2M	0.12%	220

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Caption Management's XENE Position: Q3 2025 in Review

Caption Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2025, closing a stake of 100,940 shares — an estimated $3.56M sold.

Caption Management first reported a position in XENE in Q3 2023 and held it in 2 quarters. The position peaked at $3.16M in Q2 2025. 219 funds tracked by Wall St. Rank hold XENE as of Q3 2025.

Caption Management reported no remaining Xenon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Caption Management sold 100,940 Xenon Pharmaceuticals shares in Q3 2025, an estimated $3.56M.
Caption Management first reported a position in Xenon Pharmaceuticals in Q3 2023 and held it in 2 quarters.
Caption Management's Xenon Pharmaceuticals position peaked at $3.16M in Q2 2025.
219 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.